{"id":"hydromorphone-liquid-oral","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"30-40","effect":"Drowsiness"},{"rate":"15-25","effect":"Dizziness"},{"rate":null,"effect":"Respiratory depression"},{"rate":"10-15","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydromorphone activates mu opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. This results in potent analgesia suitable for moderate to severe pain management. The liquid oral formulation allows for flexible dosing and is commonly used in palliative care and acute pain settings.","oneSentence":"Hydromorphone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and sedation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:06.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain"},{"name":"Cancer pain"},{"name":"Palliative care"}]},"trialDetails":[{"nctId":"NCT04240626","phase":"PHASE4","title":"Multimodal Analgesia Effect on Post Surgical Patient","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2021-01-20","conditions":"Obesity, Morbid, Surgery, Bariatric Surgery Candidate","enrollment":60},{"nctId":"NCT03767933","phase":"PHASE2","title":"Non-Steroidal or Opioid Analgesia Use for Children With Musculoskeletal Injuries","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2019-04-20","conditions":"Musculoskeletal Injury","enrollment":710},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT01447212","phase":"PHASE3","title":"Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-12","conditions":"Opioid Dependence, Heroin Dependence","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydromorphone, liquid oral","genericName":"Hydromorphone, liquid oral","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydromorphone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and sedation. Used for Moderate to severe pain, Cancer pain, Palliative care.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}